The medical network "Dobrobut" paid nearly 578 million UAH in taxes in 2024. The network's revenue for the year amounted to 3.5 billion UAH, which is 52% higher than in 2023. The plan for 2025 is to increase this figure by at least one-third.

The medical network "Dobrobut" has launched its first international clinical trial to evaluate the efficacy of a new drug for Crohn's disease treatment. The investigational drug has been approved by the State Expert Center of the Ministry of Health of Ukraine. The project is led by the network’s chief gastroenterologist, internal medicine specialist Ruslan Buyanovskyi.

The medical network "Dobrobut" has launched its own cytogenetic laboratory. From now on, the full range of tests for determining the karyotype – the human chromosome set – will be performed by "Dobrobut's" own geneticists.